Baidu
map

JAMA Surg:年轻乳腺癌患者接受乳房切除手术对其生活质量的影响

2021-09-03 MedSci原创 MedSci原创

年轻乳腺癌患者接受乳房切除后可导致BREAST-Q量表评分显著下降,即使接受乳房重建其生活质量也会受到显著影响


乳腺癌是40岁以下女性最常见的癌症,占美国每年所有癌症的7%,有观点认为,年轻的早期乳腺癌患者若接受保乳治疗后续的复发风险可能增加,近年来,年轻乳腺癌患者的乳房切除术,特别是双侧乳房切除术比例不断增加,一度高达35%-40%。近日研究人员考察了乳腺癌手术对其长期生活质量(QOL)的影响。

本次前瞻性队列,多中心横断面研究于2016年10月至2017年11月在北美开展。参与者为40岁以下的乳腺癌患者,患者接受乳房切除手术、重建和放疗。研究的主要终点为BREAST-Q量表评分(范围0-100,得分越高,生活质量越好)。

共有560名患有0至III期乳腺癌患者参与研究,诊断时的中位年龄为36岁,年龄范围17-40岁;484例(86%)患有0-II期疾病,进行BREAST-Q量表评分的术后平均年限为5.8年。共有290名患者(52%)接受了双侧乳房切除术,110名患者(20%)接受了单侧乳房切除术,160名患者(28%)接受了保乳治疗。在乳房切除术患者中,357例(89%)进行了重建,181例(45%)接受了放疗。在多变量分析中,与自体组织乳房重建相比,植入物重建导致BREAST-Q量表评分下降(β = −7.4),而复杂重建与身体健康状况较差相关(β = −14.0)。

研究发现,年轻乳腺癌患者接受乳房切除后可导致BREAST-Q量表评分显著下降,即使接受乳房重建其生活质量也会受到显著影响

原始出处:

Laura Dominici et al. Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surg. September 1, 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769267, encodeId=66801e6926716, content=<a href='/topic/show?id=e392489653e' target=_blank style='color:#2F92EE;'>#年轻乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48965, encryptionId=e392489653e, topicName=年轻乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e12138003973, createdName=bshuang, createdTime=Sat Sep 18 08:40:46 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543382, encodeId=2b581543382a9, content=<a href='/topic/show?id=296f319115a' target=_blank style='color:#2F92EE;'>#切除手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31911, encryptionId=296f319115a, topicName=切除手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c013575702, createdName=ms9476844295372110, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571279, encodeId=577415e1279f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036816, encodeId=90dc1036816f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Sep 03 20:40:46 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769267, encodeId=66801e6926716, content=<a href='/topic/show?id=e392489653e' target=_blank style='color:#2F92EE;'>#年轻乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48965, encryptionId=e392489653e, topicName=年轻乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e12138003973, createdName=bshuang, createdTime=Sat Sep 18 08:40:46 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543382, encodeId=2b581543382a9, content=<a href='/topic/show?id=296f319115a' target=_blank style='color:#2F92EE;'>#切除手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31911, encryptionId=296f319115a, topicName=切除手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c013575702, createdName=ms9476844295372110, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571279, encodeId=577415e1279f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036816, encodeId=90dc1036816f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Sep 03 20:40:46 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769267, encodeId=66801e6926716, content=<a href='/topic/show?id=e392489653e' target=_blank style='color:#2F92EE;'>#年轻乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48965, encryptionId=e392489653e, topicName=年轻乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e12138003973, createdName=bshuang, createdTime=Sat Sep 18 08:40:46 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543382, encodeId=2b581543382a9, content=<a href='/topic/show?id=296f319115a' target=_blank style='color:#2F92EE;'>#切除手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31911, encryptionId=296f319115a, topicName=切除手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c013575702, createdName=ms9476844295372110, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571279, encodeId=577415e1279f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036816, encodeId=90dc1036816f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Sep 03 20:40:46 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769267, encodeId=66801e6926716, content=<a href='/topic/show?id=e392489653e' target=_blank style='color:#2F92EE;'>#年轻乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48965, encryptionId=e392489653e, topicName=年轻乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e12138003973, createdName=bshuang, createdTime=Sat Sep 18 08:40:46 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543382, encodeId=2b581543382a9, content=<a href='/topic/show?id=296f319115a' target=_blank style='color:#2F92EE;'>#切除手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31911, encryptionId=296f319115a, topicName=切除手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c013575702, createdName=ms9476844295372110, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571279, encodeId=577415e1279f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 05 08:40:46 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036816, encodeId=90dc1036816f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Sep 03 20:40:46 CST 2021, time=2021-09-03, status=1, ipAttribution=)]
    2021-09-03 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Oncologist:阿拉伯女性乳腺癌患者体细胞突变的分子谱和频率模式

该研究阐明了阿拉伯女性乳腺癌患者体细胞突变的频率,表明跟西方人群有一定的差异。这些数据需要更大规模的流行病学研究,评估此类突变在预后和个性化管理中的作用。

J Clin Oncol:高危型乳腺导管原位癌肿瘤切除术后是否需要放疗?

放疗可显著降低高危型 DCIS 患者的所有和侵袭性 IBR,而且该效益可持续15年之久

“予她圆满”保乳公益展暨”保乳日”在沪闪亮开启

立足创新突破,助力乳腺癌诊疗全面发展

Radiology:乳腺MRI,让乳腺癌患者放心的“变美”!

现阶段,尽管保乳手术已成为大多数乳腺癌患者的首选术式,但仍有大约 30% 的乳腺癌患者仅能进行乳房切除术。

Clin Cancer Res:口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性

口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的安全性良好,而且表现出初步的抗肿瘤活性

Nutrients:近年来绝经后乳腺癌患者化疗期间的代谢变化

乳腺癌患者越来越重视体力活动和营养,因此代谢变化得到了较为明显的改善。

Baidu
map
Baidu
map
Baidu
map